Angiotensin converting enzyme inhibitor use soon after renal transplantation: A randomized, double-blinded placebo-controlled safety study

Clinical Transplantation

Volumn 25, Issue 6, 2011, Pages 843-848

  Glicklich, Daniel ^a   Gordillo, Roberto ^a   Supe, Katarina ^a   Tapia, Raquel ^a   Woroniecki, Robert ^a   Solorzano, Clemencia ^a   Coco, Maria ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Renal transplant

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; CREATININE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; POTASSIUM ION; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; VALGANCICLOVIR;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HUMAN; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; SAFETY;

EID: 83455235264     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01372.x     Document Type: Article

References (13)

1. Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009: 4: 860.
2. Geara AS, Azzi J, Jurewicz M, Abdi R. The renin angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev 2009: 23: 151.
3. Hiremath S, Fergusson D, Doucette S et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007: 7: 2350.
4. Lorenz M, Billensteiner E, Bodingbauer M et al. The effect of ACE inhibitor and angiotensin II blocker therapy on early post transplant kidney graft function. Am J Kidney Dis 2004: 43: 1065.
5. Heinze G, Collins S, Benedict MA et al. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006: 82: 1441.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009: 9(Suppl 3): S1.
7. Rush DN, Cockfield SM, Nickerson PW et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation 2009: 88: 897.
8. Midvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001: 72: 1787.
9. Cruzado JM, Rico J, Grinyo JM. The renin angiotensin system blockade in kidney transplantation: pros and cons. Transplant Int 2008: 21: 304.
10. Suwelack B, Kobelt V, Erfmann M et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transplant Int 2003: 16: 313.
11. Formica RN, Friedman AL, Lorber MI et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006: 21: 1389.
12. Tylicki L, Biedunkiewicz B, Chamienia A et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007: 7: 243.
13. El-Agroudy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003: 23: 300.